Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Nurix Therapeutics (NRIX) to $16 from $17 and keeps an Equal Weight rating on the shares. Nurix’s pipeline is on track with clinical updates expected in 2H25, while bexobrutideg remains the key driver for the stock, with Nurix increasing investment behind the program, the analyst says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Buy Rating for Nurix Therapeutics Driven by Strong Financials and Upcoming Clinical Milestones
- Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright
- Top 3 Trending Stocks, According to Analysts – 7/11/2025
- Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts
- Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer